Isaac Manke - 18 Mar 2026 Form 3 Insider Report for Addex Therapeutics Ltd. (ADXN)

Reporting relationship: Director
Issuer ticker: ADXN
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 11:06:22 UTC
Prior SEC filing: 02 Jan 2026
Next SEC filing: 21 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Lenaic Nathanael Teyssedou by power of attorney

Key filing fact

Isaac Manke filed Form 3 for Addex Therapeutics Ltd. (ADXN) on 18 Mar 2026.

Key facts

This page summarizes Isaac Manke's Form 3 filing for Addex Therapeutics Ltd. (ADXN).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2026, 11:06.

Change

Previous filing in this sequence was filed on 02 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001622769 Primary reporting owner

Manke Isaac

Relationship: Director
Address: 405 DORADO BEACH EAST, DORADO
Signature: /s/ Lenaic Nathanael Teyssedou by power of attorney
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADXN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 219,561
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADXN holding Derivative

Stock-option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $0.0640
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents 219,561 shares of Common Stock listed on SIX Swiss Exchange.

Footnote F2

The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.

Footnote F3

The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

SEC remarks

Exhibit List : Exhibit 24 - Power of Attorney